Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of HIV-1 Associated Malignancies

Inclusion Criteria

DISEASE CHARACTERISTICS:

- Participants must have a diagnosis of a malignancy or clinical findings suggestive of
a possible HIV-associated malignancy of one of four types:

- Diffuse large B-cell lymphoma

- Non-small cell lung malignancy

- Anal cancer

- Cervical cancer

- The presence of any of the following conditions will exclude a participant from study
enrollment:

- Absence of sufficient diagnostic tumor-biopsy tissue material to meet the
protocol requirements for baseline specimen submission (minimum specimen size of
10 x 10 x 2 mm); repeat tumor biopsy will not be performed solely to meet the
protocol specimen-collection requirements

- Participants whose biopsies, for the purpose of this protocol, show a diagnosis
of anal intraepithelial neoplasia or cervical intraepithelial neoplasia

- Prior treatment for the study malignancy (including neo-adjuvants), since
treatment can affect the mutational spectra of tumors

- HIV infection based on serologic documentation of HIV infection at any time prior to
study entry, as evidenced by positive enzyme-linked immunosorbent assay (ELISA),
positive western blot, or any other Food and Drug Administration (FDA)-approved
(licensed) HIV test; alternatively, this documentation may include a record that
another physician has documented that the patient has HIV based on prior ELISA and
western blot, or other approved diagnostic tests

PATIENT CHARACTERISTICS:

- Participants must be willing and able to sign an IRB-approved informed consent
document

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics